References: Gao LW, Yin J, Hu YH, et al. The epidemiology of paediatric Mycoplasma pneumoniae pneumonia in North China: 2006 to 2016[J]. Epidemiol Infect, 2019, 147: e192. (PMID: 10.1017/S0950268819000839PMC651860231364532)
Yang J, Hooper WC, Phillips DJ, et al. Cytokines in Mycoplasma pneumoniae infections[J]. Cytokine Growth Factor Rev, 2004, 15(2-3): 157- 168. (PMID: 10.1016/j.cytogfr.2004.01.00115110799)
Sreejit G, Flynn MC, Patil M, et al. S100 family proteins in inflammation and beyond[J]. Adv Clin Chem, 2020, 98: 173- 231. (PMID: 10.1016/bs.acc.2020.02.00632564786)
Hidalgo A, Libby P, Soehnlein O, et al. Neutrophil extracellular traps: from physiology to pathology[J]. Cardiovasc Res, 2022, 118(13): 2737- 2753. (PMID: 10.1093/cvr/cvab329PMC958656234648022)
马开树, 刘成坤, 屈开新, 等. 血清S100A8/A9与社区获得性肺炎患者严重程度及预后关联的回顾性队列研究[J]. 临床肺科杂志, 2022, 27(12): 1850- 1856. (PMID: 10.3969/j.issn.1009-6663.2022.12.014)
Havelka A, Sejersen K, Venge P, et al. Calprotectin, a new biomarker for diagnosis of acute respiratory infections[J]. Sci Rep, 2020, 10(1): 4208. (PMID: 10.1038/s41598-020-61094-zPMC706026232144345)
Xie S, Wang J, Tuo W, et al. Serum level of S100A8/A9 as a biomarker for establishing the diagnosis and severity of community-acquired pneumonia in children[J]. Front Cell Infect Microbiol, 2023, 13: 1139556. (PMID: 10.3389/fcimb.2023.1139556PMC1017266337180431)
国家卫生健康委员会. 儿童肺炎支原体肺炎诊疗指南(2023年版)[J]. 传染病信息, 2023, 36(4): 291- 297. (PMID: 10.3969/j.issn.1007-8134.2023.04.002)
Liu B, Chang X, Yan N. Clinical analysis of the epidemiology and changes in inflammatory indexes of Mycoplasma pneumonia in acute and recovery stage pediatric patients[J]. Transl Pediatr, 2022, 11(10): 1645- 1655. (PMID: 10.21037/tp-22-416PMC963645936345443)
Otheo E, Rodríguez M, Moraleda C, et al. Viruses and Mycoplasma pneumoniae are the main etiological agents of community-acquired pneumonia in hospitalized pediatric patients in Spain[J]. Pediatr Pulmonol, 2022, 57(1): 253- 263. (PMID: 10.1002/ppul.2572134633153)
Tong L, Huang S, Zheng C, et al. Refractory Mycoplasma pneumoniae pneumonia in children: early recognition and management[J]. J Clin Med, 2022, 11(10): 2824. (PMID: 10.3390/jcm11102824PMC914410335628949)
Zhu Y, Luo Y, Li L, et al. Immune response plays a role in Mycoplasma pneumoniae pneumonia[J]. Front Immunol, 2023, 14: 1189647. (PMID: 10.3389/fimmu.2023.1189647PMC1025069437304280)
Huang X, Li D, Liu F, et al. Clinical significance of D-dimer levels in refractory Mycoplasma pneumoniae pneumonia[J]. BMC Infect Dis, 2021, 21(1): 14. (PMID: 10.1186/s12879-020-05700-5PMC778741433407216)
Yang M, Meng F, Gao M, et al. Cytokine signatures associate with disease severity in children with Mycoplasma pneumoniae pneumonia[J]. Sci Rep, 2019, 9(1): 17853. (PMID: 10.1038/s41598-019-54313-9PMC688279331780733)
邹映雪. 肺炎支原体肺炎炎症指标异常的临床意义[J]. 中华实用儿科临床杂志, 2021, 36(16): 1209- 1214. (PMID: 10.3760/cma.j.cn101070-20210725-00879)
Zhou Y, Hu M, Ye B, et al. Early prediction of necrotizing pneumonia from Mycoplasma pneumoniae pneumonia with large pulmonary lesions in children[J]. Sci Rep, 2020, 10(1): 19061. (PMID: 10.1038/s41598-020-76083-5PMC764307933149220)
张芙荣, 周卫芳, 李玉琴, 等. 中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值在重症肺炎支原体肺炎中的诊断价值[J]. 中华实用儿科临床杂志, 2022, 37(4): 260- 264. (PMID: 10.3760/cma.j.cn101070-20201013-01612)
牛艳华, 孙超, 王超, 等. 重症肺炎支原体肺炎患儿的危险因素分析[J]. 上海医学, 2023, 46(6): 388- 392. (PMID: 10.19842/j.cnki.issn.0253-9934.2023.06.006)
Fang C, Mao Y, Jiang M, et al. Pediatric Critical Illness Score, clinical characteristics and comprehensive treatment of children with severe Mycoplasma pneumoniae pneumonia[J]. Front Surg, 2022, 9: 897550. (PMID: 10.3389/fsurg.2022.897550PMC917493435693303)
Lee KL, Lee CM, Yang TL, et al. Severe Mycoplasma pneumoniae pneumonia requiring intensive care in children, 2010-2019[J]. J Formos Med Assoc, 2021, 120(1 Pt 1): 281- 291. (PMID: 10.1016/j.jfma.2020.08.01832948415)
Guo S, Mao X, Liang M. The moderate predictive value of serial serum CRP and PCT levels for the prognosis of hospitalized community-acquired pneumonia[J]. Respir Res, 2018, 19(1): 193. (PMID: 10.1186/s12931-018-0877-xPMC616790130285748)
Wang J, Mao J, Chen G, et al. Evaluation on blood coagulation and C-reactive protein level among children with Mycoplasma pneumoniae pneumonia by different chest imaging findings[J]. Medicine (Baltimore), 2021, 100(3): e23926. (PMID: 10.1097/MD.0000000000023926PMC783786833545964)
Zhang C, Zhang Q, Du JL, et al. Correlation between the clinical severity, bacterial load, and inflammatory reaction in children with Mycoplasma pneumoniae pneumonia[J]. Curr Med Sci, 2020, 40(5): 822- 828. (PMID: 10.1007/s11596-020-2261-6PMC759504533123897)
乔红梅, 庞焕香, 张云峰, 等. 肺炎支原体肺炎患儿IL-6、IL-10、TNF-α的变化[J]. 临床儿科杂志, 2012, 30(1): 59- 61. (PMID: 10.3969/j.issn.1000-3606.2012.01.015)
Fernandes CD, Arriaga MB, Costa MCM, et al. Host inflammatory biomarkers of disease severity in pediatric community-acquired pneumonia: a systematic review and meta-analysis[J]. Open Forum Infect Dis, 2019, 6(12): ofz520. (PMID: 10.1093/ofid/ofz520PMC691702831867405)
李娟, 颜维孝, 马如海. 重症MPP患儿外周血Th1/Th2类细胞因子变化及对近期预后不良的预测分析[J]. 中国免疫学杂志, 2023, 39(10): 2222- 2226. (PMID: 10.3969/j.issn.1000-484X.2023.10.036)
Tian F, Chen LP, Yuan G, et al. Differences of TNF-α, IL-6 and gal-3 in lobar pneumonia and bronchial pneumonia caused by Mycoplasma pneumoniae [J]. Technol Health Care, 2020, 28(6): 711- 719. (PMID: 10.3233/THC-19201132200365)
Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance[J]. Eur J Immunol, 2010, 40(7): 1830- 1835. (PMID: 10.1002/eji.20104039120583029)
Jin X, Zhu Y, Zhang Y, et al. Assessment of levels of D-dimer and interferon-γ in pediatric patients with Mycoplasma pneumoniae pneumonia and its clinical implication[J]. Exp Ther Med, 2018, 16(6): 5025- 5030. (PMID: 10.3892/etm.2018.6873PMC625683630546408)
Bai S, Wang W, Ye L, et al. IL-17 stimulates neutrophils to release S100A8/A9 to promote lung epithelial cell apoptosis in Mycoplasma pneumoniae -induced pneumonia in children[J]. Biomed Pharmacother, 2021, 143: 112184. (PMID: 10.1016/j.biopha.2021.11218434562768)
No Comments.